Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide With Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

NCT06565611 is registered in ClinicalTrials.gov with Palatin Technologies, Inc as lead sponsor.

NCT NCT06565611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06565611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide With Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Lead sponsor
Palatin Technologies, Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 5, 2024
Completion date
March 31, 2025
Enrollment
108 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

obesity